Nowadays the U.S. and China are the most important pharmaceutical markets for drug development and manufacturing. During 2015, the U.S. Food and Drug Administration (FDA) approved 45 novel drugs, hitting a 19-year record high, which is extremely encouraging for the pharmaceutical industry worldwide. In the meantime, the China Food and Drug Administration (CFDA) has started a reform aiming to solve backlogs of review and approval process for drugs and medical devices. This extensive reform has brought many critical challenges for every multinational pharmaceutical company.
We will offer you the latest legal and regulatory information, provide face-to-face opportunities with directors from both FDA and CFDA, and bring the top regulatory professionals to help you tap into these new situations.